Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent

  Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent

Business Wire

NEW YORK -- March 12, 2014

Pfizer Inc. confirmed today that the United States District Court for the
Eastern District of Virginia granted summary judgment invalidating the reissue
patent (U.S. Patent No. RE44,048), covering methods of treating osteoarthritis
and other approved conditions with celecoxib, the active ingredient in
Celebrex®.

Pfizer disagrees with the ruling and will pursue all available remedies,
including an immediate appeal of the court’s decision.

A trial was scheduled to begin on March 19, 2014, for infringement of the
reissue patent in the action brought by Pfizer against the generic companies
Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Watson
Laboratories, Inc., Lupin Pharmaceuticals, USA, Inc., Apotex Corp., and
Apotex, Inc.

Each of these generic companies previously filed an abbreviated new drug
application with the United States Food and Drug Administration seeking
approval to market a generic form of celecoxib in the United States beginning
on May 30, 2014, when Pfizer’s basic Celebrex® compound patent (including the
six-month pediatric exclusivity period)expires. This is eighteen months prior
to the December 2, 2015 expiration (including the six-month pediatric
exclusivity period) of the reissue patent.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to
people that extend and significantly improve their lives. We strive to set the
standard for quality, safety and value in the discovery, development and
manufacture of health care products. Our global portfolio includes medicines
and vaccines as well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and emerging
markets to advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our responsibility as
one of the world's premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and local communities to
support and expand access to reliable, affordable health care around the
world. For more than 150 years, Pfizer has worked to make a difference for all
who rely on us. To learn more, please visit us at www.pfizer.com.

Contact:

Pfizer Inc.
Media:
Steve Danehy, 212-733-1538
or
Investor:
Ryan Crowe, 212-733-8160
 
Press spacebar to pause and continue. Press esc to stop.